Compare ERO & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERO | SUPN |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.0B |
| IPO Year | 2021 | 2010 |
| Metric | ERO | SUPN |
|---|---|---|
| Price | $29.75 | $44.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $36.50 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 1.2M | 536.4K |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $392,755,000.00 |
| Revenue This Year | $51.94 | $22.70 |
| Revenue Next Year | $2.43 | $19.14 |
| P/E Ratio | $22.61 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.79 | $31.16 |
| 52 Week High | $39.80 | $59.68 |
| Indicator | ERO | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 53.53 | 40.36 |
| Support Level | $27.82 | $43.67 |
| Resistance Level | $32.62 | $52.36 |
| Average True Range (ATR) | 1.77 | 1.43 |
| MACD | 0.16 | 0.01 |
| Stochastic Oscillator | 61.49 | 46.73 |
Ero Copper Corp is a high-margin, high-growth copper producer with operations in Brazil. Its primary asset is its 99.6% ownership interest in Mineracao Caraiba S.A., held indirectly through its wholly-owned subsidiary. The company also owns a 97.6% ownership interest in NX Gold S.A. indirectly through its wholly-owned subsidiary. Its reporting segments include its three operating mines in Brazil, the Caraiba Operations, the Tucuma Operation, and the Xavantina Operations, and its corporate head office in Canada.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.